|
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma
|
20 March 2025 |
|
FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
|
21 February 2025 |
|
Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
|
18 October 2024 |
|
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
|
18 September 2024 |
|
European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
|
17 January 2024 |
|
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies
|
19 December 2023 |
|
Roche's subcutaneous injection of Tecentriq recommended by the EU's CHMP for multiple cancer types
|
14 November 2023 |
|
Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
|
27 October 2023 |
|
Roche's Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
|
06 September 2023 |
|
Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems
|
08 May 2023 |
|
Roche announces donation of essential medicines and diagnostic solutions to the people affected by the devastating earthquake in Türkiye and Syria
|
15 February 2023 |
|
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
|
20 January 2023 |
|
Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options
|
15 December 2022 |
|
Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
|
12 August 2022 |
|
Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
|
04 August 2022 |
|
FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma
|
06 July 2022 |
|
FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
|
31 May 2022 |
|
Roche develops unique PCR tests to detect the monkeypox virus
|
27 May 2022 |
|
Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
|
17 May 2022 |
|
Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
|
12 May 2022 |